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Background: One of the key genes that regulate human brain size, MCPH1 has evolved under strong Darwinian
positive selection during the evolution of primates. During this evolution, the divergence of MCPH1 protein
sequences among primates may have caused functional changes that contribute to brain enlargement.
Results: To test this hypothesis, we used co-immunoprecipitation and reporter gene assays to examine the
activating and repressing effects of MCPH1 on a set of its down-stream genes and then compared the functional
outcomes of a series of mutant MCPH1 proteins that carry mutations at the human- and great-ape-specific sites.
The results demonstrate that the regulatory effects of human MCPH1 and rhesus macaque MCPH1 are different in
three of eight down-stream genes tested (p73, cyclinE1 and p14ARF), suggesting a functional divergence of MCPH1
between human and non-human primates. Further analyses of the mutant MCPH1 proteins indicated that most of
the human-specific mutations could change the regulatory effects on the down-stream genes. A similar result was
also observed for one of the four great-ape-specific mutations.
Conclusions: Collectively, we propose that during primate evolution in general and human evolution in particular,
the divergence of MCPH1 protein sequences under Darwinian positive selection led to functional modifications,
providing a possible molecular mechanism of how MCPH1 contributed to brain enlargement during primate
evolution and human origin.
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A dramatic increase in brain size is one of the hallmarks
of human evolution, but despite the significance of
this trait, the causal molecular mechanism underlying
this expansion is unclear [1]. Until recently, addressing
this question with genetic tools has been difficult because
the dramatically enlarged brain is a human-specific trait.
Genetic studies of a rare brain developmental disorder,
human autosomal primary microcephaly syndrome
(MCPH, OMIM251200), have uncovered a set of genes
that regulate brain development. To date, seven genes have
been identified as being responsible for this syndrome:
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reproduction in any medium, provided the orof hTERT expression) [2,3], WDR62 (WD repeat domain
62; MCPH2) [4-6], CDK5RAP2 (cyclin-dependnet kin-
ase 5 regulatory associated protein 2; MCPH3) [7],
CEP152 (centrosomal protein 152 kDa; MCPH4) [8],
ASPM (abnormal spindle like microcephaly associated
protein; MCPH5) [9], and CENPJ (centromeric protein
J; MCPH6) [7] and STIL (SCL/TAL1 interrupting locus;
MCPH7) [10].
Previous evolutionary analyses of these microcephaly
genes showed that four of them, ASPM, CDK5RAP2,
CENPJ and MCPH1, evolved rapidly under Darwinian
positive selection during the evolution of human and
non-human primates [11-16]. ASPM also experienced
positive selection across anthropoids [14-16], while
CDK5RAP2 and CENPJ showed accelerated rates of
non-synonymous substitutions over the course of pri-
mate evolution [11,16]. The signal of positive selection
on MCPH1 was observed in the common ancestor of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[12], although another study on MCPH1 only detected
positive selection in the anthropoids as a whole and no
particular acceleration in the human lineage [16]. This
rapid evolution suggests these genes may have had a
key role in the evolutionary enlargement of the brain,
although the link of CENPJ and MCPH1 to the evolution
of gross brain size was not confirmed in the association
analysis of absolute neonatal brain size among primates
[16]. Among the four rapidly evolving microcephaly genes,
only ASPM has been experimentally studied to detect the
evolutionary consequence of protein sequence changes;
mice carrying a truncated ASPM protein were shown to
have reductions of both brain and testis size, while the
transgenic mouse carrying human ASPM could rescue this
phenotype, but did not cause any additional enlargement of
the brain [17].
MCPH1 was the first gene identified as being responsible
for autosomal recessive primary microcephaly, charac-
terized by significantly reduced brain volume, mental
retardation and premature chromosome condensation
(PCC) syndrome [2,18]. The MCPH1 gene encodes a
2,508-bp-long coding sequence (CDS) with 14 exons,
spanning about 240 kb at 8p23. The MCPH1 protein
contains three BRCA1-Carboxyl Terminal (BRCT) do-
mains, including one N terminal BRCT domain and a
tandem pair at the C terminus. Numerous studies have
implied that the BRCT domains of MCPH1 function as
the key component for protein-protein interaction; this
seems likely as the interaction of the MCPH1 tandem
BRCT domains with proteins like E2F1 and r-H2AX is
required for the activation of cell cycle checkpoint,
DNA repair and apoptosis [19-23]. Several studies have
likewise suggested that MCPH1 may also function as a
tumor suppressor [3,23].
Evolutionary studies of MCPH1 have demonstrated a
rapid change in protein sequence associated with the
brain enlargement during primate evolution and human
origin. Interestingly, during two key taxonomic transi-
tions in primates, that is, between lesser apes and great
apes, and between great apes and humans, absolute
brain volume was greatly enlarged, and MCPH1 might
be involved in this process [12]. Additionally, MCPH1 is
also highly polymorphic in human populations and still
carries the molecular signature of on-going positive
selection [12]. Human population studies have reported
a sex-specific association between a MCPH1 sequence
variant and brain volume [24,25]. These results suggest
that the protein sequence changes, especially the human-
specific changes of MCPH1 may have caused the functional
changes that explain the genetic basis for the evolution of
brain size in primates.
Previously, the MCPH1 protein has been shown to
play an essential role during cell cycle and cell apoptosisand it can physically interact with E2F1 to form a
complex and bind the promoters of the target genes for
regulating their transcriptional activities [19]. Beyond
this, MCPH1 alone can also function as a transcriptional
regulator, and we previously demonstrated MCPH1 could
function as a transcriptional repressor [26]. Together,
these regulatory mechanisms allow the experimental
testing of the functional changes of MCPH1 during pri-
mate evolution.
To detect if the protein sequence divergence of MCPH1
among primates may confer any functional alterations, we
selected eight known down-stream genes regulated by
E2F1 and MCPH1: p73 [19], p107 [19], p18 [27], p27 [28],
p14ARF [19], Caspase7 [19], CyclinE1 [19] and hTERT
[26]. These genes are involved in cell proliferation and
apoptosis, critical processes regulating brain development
(see Additional file 1: Figure S1). We tested the activating
effects (together with E2F1) and the repressing effects
(MCPH1 alone) of MCPH1 on these genes’ promoter
when introducing mutations at the sites containing
human- and great-ape-specific amino acid changes. Our
results demonstrated that most of the human-specific
amino acid substitutions could influence the regulatory
effects of MCPH1 on the down-stream genes, and a similar
effect was also seen for one of the four great-ape-specific
changes, suggesting that the species and lineage specific
mutations of MCPH1 are indeed functional and potentially
contributed to brain enlargement over the course of
primate evolution.
Results
Identification of lineage-specific MCPH1 amino acid
substitutions
In order to identify lineage-specific amino acid substitutions,
MCPH1 orthologs of representative primate and other
mammalian species were obtained from the NCBI, EMBL
and UniProt databases. We used a total of 11 species includ-
ing 7 primates (human, great apes, lesser ape, Old World
monkey and New World monkey) and 4 other representa-
tive mammalian species (mouse, rat, dog and cow) (Figure 1).
Using MUSCLE and Clustal W, we aligned the MCPH1
protein sequences (see Additional file 2: Figure S2). During
primate evolution, there are two key taxonomic transitions
accompanied by brain enlargements (between lesser apes
and great apes, and between great apes and humans). We
identified nine sites containing substitutions considered as
human-specific sites that occur in the human lineage but
are relatively conserved in the other species (M96, S101,
V310, H314, T377, Y425, L442, R485 and P835; Figure 1,
Additional file 3: Table S1). We further selected four sites
containing substitutions considered as great-ape-specific
since they occurred in the ancestor of Hominidae (I161,
E167, A510 and S841; Figure 1, Additional file 3: Table S1).
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Figure 1 Schematic map of MCPH1 protein domains labeled with lineage-specific amino acid substitutions. Sites containing human
specific substitutions are marked with shadows, and the two dramatic brain size enlargement events that coincided with the molecular
signatures of Darwinian positive selection during primate evolution are indicated.
Shi et al. BMC Biology 2013, 11:62 Page 3 of 11
http://www.biomedcentral.com/1741-7007/11/62amino acid substitutions are shown in Additional file 3:
Table S1 and the schematic map of the MCPH1 protein
domains labeled with the lineage-specific substitutions
are shown in Figure 1. All these lineage-specific sites
were selected to generate mutant MCPH1 proteins for the
reporter gene assays in order to test their functional effects.
Test of protein-protein interaction between MCPH1
and E2F1
Previous studies suggested human MCPH1 (hMCPH1)
could interact with E2F1 in vitro and in vivo [19]. To
test if the non-human primate MCPH1 can also interact
with E2F1, we cloned the rhesus macaque MCPH1
(mMCPH1). The results of the co-immunoprecipitation
assay showed that mMPCH1 can also directly interact
with E2F1, and no difference was observed for the intensity
of the interaction with E2F1 between hMCPH1 and
mMCPH1 (Figure 2A). Given the established MCPH1-
E2F1 interaction in human cell lines [19], this protein-
protein interaction mechanism seems likely to have
been conserved during primate evolution. We also
conducted a cellular co-localization assay for both
mMCPH1 and hMCPH1, and the results indicated that
both were co-localized with E2F1 (Figure 2B), consistent
with the results of the co-immunoprecipitation assay.
Divergent effects of hMCPH1 and mMCPH1 on
transcriptional regulation
MCPH1 interacts with E2F1 to enhance its transactivation
activity by forming a complex, which binds to the
promoters of the E2F1 target genes, including p73,Caspase and RAD51, among others [19]. We, therefore,
tested the enhancing effect of MCPH1 using the E2F4B
reporter vector commonly used as the positive control
in testing the transactivation activity of E2F1 [29]. The
expression of the HA-tagged MCPH1 and E2F1 were
verified by Western blot using anti-HA monoclonal
antibodies (Figure 2C). Our results showed that hMCPH1
could significantly enhance the transactivation activity of
E2F1, but no significant effect was observed for mMCPH1
and gMCPH1 (the gibbon copy of MCPH1) (Figure 2D).
In addition, the difference between E2F1 + hMCPH1 and
E2F1 + mMCPH1 is significant (P <0.01, ANOVA test).
The same trend was also seen when comparing E2F1 +
hMCPH1 and E2F1 + gMCPH1, though not statistically sig-
nificant (Figure 2D). Interestingly, the difference between
E2F1 + gMCPH1 and E2F1 + mMCPH1 is significant
(P <0.05, ANOVA test), suggesting continuum of func-
tional divergence of MCPH1 during primate evolution
with a major shift in function between Old World
monkeys and apes and a probable further shift during
human evolution (Figure 2D).
To check the conservation of the E2F1 binding sites
(CGCGC), we aligned the promoter sequences of the target
genes among representative primate species. We found that
most of the E2F1 binding sites are highly conserved from
humans to marmosets (see Additional file 4: Figure S3),
ruling out the possibility of binding bias due to promoter
sequence divergence. The E2F1 protein sequences are also
highly conserved among primate species (Additional file 5:
Figure S4), ruling out the possibility that the different effect
of MCPH1 is caused by mutations in E2F1. Collectively,
Figure 2 Human and macaque MCPH1 can directly interact with E2F1. (A) Interaction of the transfected E2F1 and MCPH1 in HEK293T cells.
(B) Co-localization of MCPH1-GFP and RFP-E2F1 in HEK293T cells. White arrows indicate co-staining areas. (C) Expression of the HA-tagged human
and macaque MCPH1s were verified by Western blot using anti-HA monoclonal antibody (top panel), and the HA-tagged E2F1 was also verified
by Western blot (middle panel). The bottom panel is the actin control. (D) Quantification of E2F1 and MCPH1 transcriptional activity using the
E2F4B constructs. All histograms represent the mean ± SD of at least nine data points, including both biological and technical replicates
(* P <0.05,** P <0.01, *** P <0.001, n.s, not significant).
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between humans and nonhuman primates.
We further tested a set of E2F1 target genes (p73, p107,
p18, p27, p14ARF, Caspase7 and CyclinE1). The regulatory
network of these genes is shown in Additional file 1:
Figure S1. We found that the enhancing effect of
hMCPH1 was significantly stronger than mMCPH1 for
CyclinE1 and p73 (Figure 3A, B) and a similar trend
was also observed for p14ARF, though not significantly
(Figure 3C). No significant enhancing effects were
detected for the other four genes, p18, p27, p107 andCaspase7 (see Additional file 6: Figure S5). Consistent with
the result from the E2F4B assay, these data also suggest a
functional divergence between hMCPH1 and mMCPH1 in
enhancing the transactivation activity of E2F1.
To further test the functional divergence between
hMCPH1 and mMCPH1, we performed another assay to
detect the regulatory effect of MCPH1 alone on eight
down-stream genes (p73, p107, p18, p27, p14ARF,
Caspase7, CyclinE1 and hTERT). Among the eight genes
tested, seven showed a repressing effect for both hMCPH1
and mMCPH1, while only one, Caspase7, showed an
Figure 3 Comparison of MCPH1 enhancing and repressing effects between humans and macaques. (A) The enhancing effect difference
between hMCPH1 and mMCPH1 on the CyclinE1 promoter. (B) The enhancing effect difference between hMCPH1 and mMCPH1 on the p73
promoter. (C) The enhancing effect difference between hMCPH1 and mMCPH1 on the p14ARF promoter. For enhancing effect assay, 0.2 ug target
gene promoter construct was co-transfected with 0.2 ug HA tagged E2F1 per/well or 0.2 ug HA tagged E2F1 and 0.2 ug HA tagged hMCPH1 per/
well or 0.2 ug HA tagged E2F1 and 0.2 ug HA tagged mMCPH1 per well in 24-well plates in HEK923T cells, Renilla was used as the internal
control. The HA-tagged empty vector was used as the negative control. (D) The repressing effect difference between hMCPH1 and mMCPH1 on
the CyclinE1 promoter. (E) The repressing effect difference between hMCPH1 and mMCPH1 on the p73 promoter. (F) The repressing effect
difference between hMCPH1 and mMCPH1 on the p14ARF promoter. For repression assay, 0.2 ug target gene promoter construct was
co-transfected with 0.2 ug HA tagged hMCPH1 per/well or 0.2 ug HA tagged mMCPH1 per/well in 24-well plates in HEK923T cells, Renilla was
used as the internal control. The HA-tagged empty vector was used as the negative control. All histograms represent the mean ± SD of at least
nine data points including both biological and technical replicates (* P <0.05,** P <0.01, *** P <0.001, n.s, not significant).
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hMCPH1 and mMCPH1, three genes (CyclinE1, p73
and p14ARF) showed significant differences (P <0.05) of
repressing effect (Figure 3D–F), the same three which
showed enhancing differences between hMCPH1 and
mMCPH1 in the E2F1-MCPH1 transactivation assay
(Figure 3A-C). For CyclinE1 and p14ARF, hMCPH1
showed a stronger repressing effect than mMCPH1,
while the opposite effect was observed for p73. We
did not detect significant between-species differences
for the other four genes with repressing effect (p18,
p27, p107 and hTERT) though the trend was the same
(see Additional file 7: Figure S6). Caspase 7 was the only
gene with an activating effect, and we also observed a
significant difference between hMCPH1 and mMCPH1
(P <0.05) (see Additional file 7: Figure S6D). Collectively,the data from the two reporter gene assays suggest a clear
functional divergence of MCPH1 between humans and
rhesus macaques.
Detection of regulatory changes of MCPH1 for the
human-specific sites
In order to test the functional effect of the human
specific amino acids changes, we first constructed two
mutant hMCPH1s by introducing a backward mutation
of changing the human-specific amino acid to an ancestral
amino acid (Met96Thr) and introducing a random muta-
tion (Met96Leu) at Site-96 (Figure 1). With the use of the
E2F4B transactivation reporter assay, we measured the
enhancing effect of the two mutant hMCPH1s. As shown
in Figure 4A, both mutant hMCPH1s showed a significantly
decreased enhancing effect as compared with the wild-type
Figure 4 Results of assays testing transcriptional regulations of mutant MCPH1s containing mutations at human-specific sites. (A-C)
The results of the E2F4B assay testing the changes of enhancing effect. (D-E) The results of the p14ARF assay testing the repressing effect. All
histograms represent the mean ± SD of at least nine data points including both biological and technical replicates (* P <0.05,** P <0.01,
*** P <0.001, n.s, not significant).
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and mMCPH1, suggesting that the human-specific
amino acid change at Site-96 can influence the enhancing
effect of MCPH1.
We next generated a series of mutant hMCPH1s carrying
backward mutations at the other eight human-specific
sites (101, 310, 314, 377, 425, 442, 485 and 835), and
tested their enhancing effects. Five of the eight mutant
hMCPH1s (101, 310, 377, 425 and 835) showed signifi-
cantly decreased enhancing effects compared with the
wild-type hMCPH1 (P <0.05) (Figure 4B, C) and the three
non-significant sites (314, 442 and 485) showed the same
trend. Among the nine human specific sites tested, the
majority (6/9) showed a significantly decreased enhancing
effect when mutated to the ancestral amino acids,
suggesting most of the human-specific MCPH1 amino
acid changes are in fact functional.
We also tested the repressing effect on p14ARF for the
human-specific sites. As shown in Figure 4D, E, we
detected a significant decrease of the p14ARF repressingeffect for five sites (101, 310, 425, 442 and 485), and the
same trend was observed for the other four, though it
was not significant. Among the five significant sites,
three (101, 310 and 425) overlapped with the six sites
showing decreased enhancing effect. Taken together, we
detected regulatory changes for most (eight out of nine)
human-specific sites, suggesting hMCPH1 has acquired
functional modifications during the origin of humans.
Detection of regulatory changes of MCPH1 for the
great-ape-specific sites
To detect the functional consequences of MCPH1’s four
great-ape-specific mutations (Figure 1), we conducted
analyses similar to that used for the human-specific sites.
The results indicated that for the enhancing assay, although
all four great-ape-specific sites showed a decreased level
as compared with the wild-type of hMCPH1, none were
statistically significant (P >0.05; Figure 5A). In contrast, in
the repressing assay, one great-ape-specific site (Site-167)
showed a significant decrease of the repressing effect
Figure 5 Results of assays testing transcriptional regulations of mutant MCPH1s containing mutations at human-specific sites.
(A) Results of the E2F4B assay testing the changes of enhancing effect. (B) Results of the p14ARF assay testing the repressing effect. All histograms
represent the mean ± SD of at least nine data points, including both biological and technical replicates (* P <0.05,** P <0.01, *** P <0.001, n.s,
not significant).
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mutation may have also caused functional modifica-
tions of MCPH1 during the evolution of the ancestor
of Hominidae.
Discussion
MCPH1 has experienced strong Darwinian positive
selection during primate evolution, but there are no data
showing functional divergence. Here we demonstrated evi-
dence of functional divergence ofMCPH1 between humans
and nonhuman primates. Most of the human-specific
amino acid changes could alter the regulatory effects of
MCPH1 on the transcription of the down-stream genes,
and a similar effect was observed for one of the four
great-ape-specific amino acid changes. Accordingly,
our data support the hypothesis that selection on
MCPH1 has resulted in functional divergence at the
protein level, which potentially contributes to changes
in the development and evolution of brain size.
Absolute brain size has increased in parallel across
primate evolution. Along the two branches we focused
on in this analysis, absolute brain volume increased from
70 to 152 ml to 230 to 565 ml during the transition
between lesser apes and great apes [30,31], and from 230
to 565 ml to 1,129 to 1,685 ml during the transition
between great apes and humans [30,31]. Previous studies
indicated that there were accelerated amino acid substitu-
tions during both the origin of Hominidae’s ancestor and of
our own species, paralleling the two brain enlargements
[12], suggesting that the amino acid substitutions of
MCPH1 were probably adaptive and may have contributed
to the brain expansion during primate evolution. In
addition, the gradient change of MCPH1’s transcription
regulation from macaque to gibbon, and to humans(Figure 2D) seems to imply a continuum of functional
divergence rather than a number of discrete shifts,
which calls for further functional tests in extensive
primate lineages.
Interestingly, all the human- and great-ape-specific
mutations are located in the non-BRCT domains (Figure 1).
Since the three BRCT domains of MCPH1 are critical for
protein-protein interaction, the amino acid changes during
primate evolution seems not to have caused drastic
functional alteration, but rather a modification of the
existing function.
Inferring the exact functional alterations of the
human-specific and great-ape-specific mutations is
difficult. Previous studies have shown that the middle
domain (residues 367 to 485) of MCPH1, where the
four human-specific mutations are located, is the binding
domain by Condensin II for homologous recombination
repair [32,33], an important mechanism for cell cycle
checkpoints and genome integrity. Concurrently, all
four human-specific sites located in this middle domain
showed altered regulatory effects when mutated into
ancestral amino acids, suggesting that the human-specific
mutations may have changed the binding property with
Condensin II. Additionally, all four human-specific mu-
tations caused changes in physicochemical properties of
amino acids (see Additional file 3: Table S1).
We also found that for the regulatory changes of the
down-stream genes, almost half (three out of eight) of the
tested genes (p73, CyclinE1 and p14ARF) had significant
differences between humans and rhesus macaques, either
in the enhancing assay with MCPH1-E2F1 or in the
repressing assay with MCPH1 alone (Figure 3), indicating
a functional divergence between humans and non-human
primates. The protein p73 is involved in both cell cycle
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important regulator of p73, especially during brain devel-
opment [35]. CyclinE1, meanwhile, is involved in cell cycle
and is a key target gene of E2F1 [36] and has been shown
to take part in the determination of the number of
neurons during mouse corticogenesis by regulating the G1
mode of cell division [37]. p14ARF is an alternate reading
frame product of CDKN2A involved in cell cycle regulation
that is also involved in self-renewal of neural stem cells
and neural development [38-41]. Additionally, human
population studies have reported that the MCPH1
sequence variants were associated with brain volume
in a sex-specific manner [24,25]. Recently, it was also
reported that MCPH1 might have contributed to the
evolution of sexual dimorphism in brain mass across
anthropoid primates [42]. In fact, two of the down-
stream genes regulated by MCPH1, p73 and cyclinE1,
were reported to be associated with sex dimorphism
during germ line development [43,44], suggesting that
the regulation of MCPH1 on brain development may
differ between males and females. Taken together, the
strengthened transactivation effect of human MCPH1 on
these down-stream genes may contribute to the greatly
enlarged neuro-progenitor pool in the human brain dur-
ing neurogenesis, which is in line with recent studies that
suggest MCPH1’s functional role in neuro-progenitor cells
through the Chk1-Cdc25-Cdk1 pathway [45,46].
Conversely, when MCPH1 acts alone as a transcription
repressor, there were also differences between humans
and rhesus macaques on the repressing effect of the
down-stream genes (p73, CyclinE1 and p14ARF), implying
that a homeostasis of gene expression regulation by
MCPH1 is required during neurogenesis.
Although we observed functional divergence of MCPH1
due to its protein sequence changes during primate evolu-
tion and human origin, it should be stressed that we did
not establish a direct link between the adaptive changes of
MCPH1 and the ever-increasing brain size in primates. As
shown in the MCPH1 knock-out mice analysis, the
truncated MCPH1 not only caused a reduction in brain
size, but also resulted in a reduction of testis size [45],
suggesting that MCPH1 may also play a role during testis
development. Accordingly, we cannot rule out the possibil-
ity that the adaptive evolution of MCPH1 in primates may
be caused by selection on other phenotypes, though the
current evidences mostly favor enlargement of the brain.
Initially proposed by King and Wilson [47], the im-
portance of cis-regulatory changes in human evolution
has recently been tested and confirmed [48]. However,
our functional data of MCPH1 suggests that protein se-
quence changes may also have significant phenotypic
effects. Hence, the evolution of an important trait like
brain function may require genetic alterations at multiple
regulatory levels.Conclusions
We demonstrated the existence of functional alterations
caused by the lineage-specific mutations of MCPH1 during
the evolution of primates, especially during the origin of
humans. The functional changes of MCPH1 are likely
executed by regulating several key down-stream genes.
Methods
Ethical statement
The research protocol of this study was approved by
the internal review board of Kunming Institute of
Zoology, Chinese Academy of Sciences (Approval ID:
SYDW-2012011).
Cell culture
The HEK293T cell line was obtained from ATCC. Cells
were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) (Gibco, Rockville, MD, USA) with 10% fetal
bovine serum (Hyclone, Logan, UT, USA) at 37°C in a
humidified atmosphere containing 5% CO2.
Cloning of the macaque and gibbon MCPH1 gene
To clone the cDNA of the macaque and gibbon MCPH1
gene, we extracted the total RNA from macaque and
gibbon brain tissue using TRIzol (Invitrogen, Carlsbad,
CA, USA). RACE was carried out using a SMARTTM
RACE cDNA amplification kit (Clontech, Palo Alto,


















The macaque MCPH1 PCR products were cloned into
the pMD-19 simple-T-vector (Takara, Tokyo, Japan),
then digested with BamH I and EcoR I, and cloned
into a pCGN-HAM vector. The gibbon MCPH1 PCR
products were cloned into the pMD-19 simple-T-vector
(Takara, Tokyo, Japan), then digested with HindIII
and AgeI, and cloned into a pCGN-HAM vector. The
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automatic sequencer).
Cloning of fluorescent MCPH1 plasmids
The full length cDNAs of human MCPH1 and macaque
MCPH1 were PCR amplified, and the PCR products
were digested with Age I and EcoR I and cloned into
frame for N-terminal fusions into the cFUGW plasmids.
The final constructs were confirmed by sequencing
(ABI-3130 automatic sequencer).
Transient transfection and luciferase reporter assays
All transfections were carried out in triplicates in the
24-well plates (Corning, Corning, NY, USA). About 2 × 105
cells were seeded for 24 h prior to transfection. Briefly,
equal numbers of cells were plated in the 24-well and
6-well plates and grown to 80% confluence. The indicated
amounts of vectors were mixed in OPTI-MEM medium
(Gibco) with Lipofectamine 2000 (Invitrogen). The solution
was incubated for about 30 minutes at room temperature
and then placed on the cultured cells. After four to six
hours, the medium was changed into DMEM (Gibco) with
10% fetal bovine serum (Hyclone). For luciferase assay, cells
were grown in the 24-well plates and transfected with the
indicated amounts of vectors, including pTK-Renilla as an
internal control, and Lipofectamine 2000 (Invitrogen) was
used. Luciferase activity was assayed 28 to 32 h after
transfection. The luciferase activity in cell extracts was
determined by the Dual-luciferase Reporter Assay
System (Promega, Madison, WI, USA) according to
the manufacturer’s protocol. The relative light units
were measured using a luminometer.
The wide range of relative luciferase activity seen in
different panels was likely due to the different amount of
cells used at each biological replicate, which did not
influence the measurement of relative activity. At least
three technical replicates were conducted for each
experiment. To avoid transfection efficiency bias, we
also performed at least three biological replicates for
the luciferase assay. The promoter constructs of p73,
p107, p18, p27, p14ARF, Caspase7 and CyclinE1 were
kindly provided by Dr. Wuhan Xiao from Institute of
Hydrobiology, Chinese Academy of Sciences, and these
constructs were published before [26,49,50].
To test the co-localization of MCPH1 and E2F1, the
GFP tagged MCPH1 expression vector was co-transfected
with the RFP tagged E2F1 expression vector into the
HEK293T cells. After 24 to 48 h, the cells were checked
under fluorescent microscopy.
Generating MCPH1 mutants
The human MCPH1 gene copy was used to generate
mutants carrying mutations at the sites with human-
specific and great-ape-specific mutations. A total of13 sites were tested, including the 9 sites containing
human-specific mutations and the 4 sites containing
great-ape-specific mutations. The mutant MCPH1s
were prepared using the QuickChange II XL site-directed
mutagenesis kit (Stratagene, La Jolla, CA, USA) and specific
oligodeoxynucleotide primer sets. The intended mutations
were confirmed by sequencing. The oligodeoxynucleotide
primers used for generating the mutant MCPH1s are
shown in Additional file 8: Table S2 and Additional file 9:
Table S3.
Co-immunoprecipitation
Flag-E2F1 and HA-MCPH1 were co-transfected into the
HEK293T cells in the six-well plates by Lipofectamine
2000 with the total amount of 16 ug DNA. After 36 to
38 h of transfection, cells were lysed with 400 ul lysis
buffer (50 ml Tris–HCl, pH = 7.4; 150 mM NaCl; 1 mM
EDTA; 1% Triton-100; 1 Mm Na3VO4) containing a
cocktail of protease inhibitors (Sigma Chemical St. Louis,
MO, USA). Cell lyses were incubated with HA agarose
beads (Sigma Chemical) overnight at 4°C with lysis buffer,
and boiled in 2 × protein loading buffer. Blots were blocked
in 0.05% Tris-buffered saline (TBS), 20% Tween and 5%
non-fat milk followed by incubation with the indicated
primary (anti-Flag (M2) from Sigma or anti-HA from
Covance, Princeton, NJ, USA) and secondary antibody
(anti-mouse from KPL, Inc. Maryland, Washington, D.C,
USA) in this buffer. Immunoreactivity was detected with
an enhanced chemiluminescence system (Pierce Protein
Biology, Rockford, IL) with colored markers (Fermentas,
Pittsburgh PA, USA) as the molecular size standard.
Western blotting
Proteins from the HEK293T cells were homogenized in
RIPA lysis buffer (50 mM Tris–HCl, pH 7.4; 150 mM NaCl;
1 mM EDTA; 1% Triton-100; 1 mM Na3VO4) containing
a cocktail of protease inhibitor (Sigma Chemical).
Extracted proteins (15 to 20 μg) were separated by SDS-
polyacrylamide gel electrophoresis and electrophoreticly
transferred to a membrane incubated with anti-HA
monoclonal antibody (Covance). Immunoreactivity was
detected with an enhanced chemiluminescence system
(Pierce Protein Biology) with colored markers (Fermentas)
as the molecular size standard.
MCPH1 protein sequence comparison among
representative mammalian species
The MCPH1 protein sequences of human, non-human
primates (chimpanzee, gorilla, orangutan, gibbon, ma-
caque and marmoset) and representative vertebrate spe-
cies (rat, mouse, cow and dog) were obtained from
the NCBI [51], EMBL [52] and UniProt [53] databases.
Orthologous sequences were aligned using Muscle in
MEGA5 [54] and Clustal W 7.0.5.2 (BioEdit software.
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Ibis Bioscience Carlsbad, CA, USA) (see Additional file 2:
Figure S2).Statistical analysis
Statistical analysis was performed using Prism 5 (GraphPad
Software, Inc. 2236 Avenida de la Playa La Jolla, CA 92037
USA), the data were analyzed using the two-tailed Student’s
t test. ANOVA test analysis using R program [55]. A
P-value of <0.05 was considered statistically significant.Database
Nucleotide sequences have been deposited to the NCBI
GeneBankTM database [56] with accession numbers
JX194162 and JX861895 for the MCPH1 coding region
sequences of rhesus macaque and gibbon.Additional files
Additional file 1: Figure S1. Summary of the E2F1 regulatory pathway.
E2F1 could up-regulate cell apoptosis associated genes p73, p14ARF,
Caspase7 and cell proliferation associated genes CyclinE1, p107, p18 and
p27 promoters’ activity. E2F1 also represses the hTERT promoter activity.
Additional file 2: Figure S2. Alignment of the full length MCPH1
protein sequences among different species including human, chimpanzee,
gorilla, orangutan, gibbon, macaque, marmoset, rat, mouse, cow and dog.
The framed sites are the human- and great-ape-specific sites.
Additional file 3: Table S1. The physicochemical properties of MCPH1
lineage specific amino acids.
Additional file 4: Figure S3. Alignment of the promoter sequences of
p73, p107, p18, p27, p14ARF, Caspase7 and hTERT (genes’ transcriptional
start site (TSS) downstream 500bp and TSS upstream 2000bp) among
primate species including human, chimpanzee, gorilla, orangutan,
macaque and marmoset. The aligned sequences are the E2F1-specific
binding sites located in the promoter region. The promoter sequences of
CyclinE1 were not available for most of the nonhuman primate species.
For Caspase 7, the promoter sequences of chimpanzee and marmoset
were not available. The numbers for positions are the distances from the
transcriptional start site.
Additional file 5: Figure S4. Alignment of the full length E2F1 protein
sequences among different primate species including human,
chimpanzee, gorilla and macaque.
Additional file 6: Figure S5. The results of the enhancing assay for the
E2F1 target genes p18, p27, p107 and Caspase7.
Additional file 7: Figure S6. The results of the repressing assay for the
target genes including p18, p27, p107, Caspase7 and TERT.
Additional file 8: Table S2. Primers used for the generation of
human-specific mutants.
Additional file 9: Table S3. Primers used for the generation of
great-ape-specific mutants.
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